Cancer cells are characterized by a higher rate of protein turnover and greater demand for
protein homeostasis compared to normal cells. In this scenario, the ubiquitin–proteasome …

The proteasome is an intracellular enzyme complex that degrades ubiquitin-tagged proteins
and thereby regulates protein levels within the cell. Given this important role in maintaining …

Targeting of the protein degradation pathway, in particular, the ubiquitin-proteasome system,
has emerged as an attractive novel cancer chemotherapeutic modality. Although …

Proteasome inhibitors (PIs), such as bortezomib, carfilzomib or NPI-0052, have excellent
clinical activity in patients with multiple myeloma and mantle cell lymphoma, and they are …

The life of every organism is dependent on the fine-tuned mechanisms of protein synthesis
and breakdown. The degradation of most intracellular proteins is performed by the ubiquitin …

Proteasome inhibitors (PIs) are effective against multiple myeloma (MM), but the
mechanisms of action and bases of individual susceptibility remain unclear. Recent work …

Background and aims Inflammatory bowel disease (IBD), comprising Crohn´ s disease and
ulcerative colitis, is characterised by chronic relapsing inflammation of the gut. Increased …

Current treatment strategies for rheumatoid arthritis (RA) consisting of disease-modifying
anti-rheumatic drugs or biological agents are not always effective, hence driving the demand …

The 20S proteasome is a multicatalytic proteinase catalysing the degradation of the majority
of intracellular proteins. Thereby it is involved in almost all basic cellular processes, which is …

Simple Summary Cancerous cells acquire genetic mutations that can lead to changes in the
amino acid sequence of proteins. These altered amino acid sequences, or “neoantigens” …